Trials / Completed
CompletedNCT02075515
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 651 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster vaccine (GSK 1437173A) | 2 doses administered intramuscularly in deltoid region of non-dominant arm. |
Timeline
- Start date
- 2014-08-13
- Primary completion
- 2015-04-29
- Completion
- 2016-04-25
- First posted
- 2014-03-03
- Last updated
- 2021-05-14
- Results posted
- 2017-05-24
Locations
8 sites across 3 countries: United States, Belgium, Canada
Source: ClinicalTrials.gov record NCT02075515. Inclusion in this directory is not an endorsement.